On November 4, join Contract Pharma and Gattefosse as we explore emerging research and formulation strategies that expand the use of lipid excipients in oral tablet development.
Join Contract Pharma and Adare Pharma Solutions on November 18th to explore how taste masking, flexible formats, modified-release technologies, and combination designs collectively position multiparticulates as an innovative approach that combines convenience, flexibility, and patient-centric oral delivery.
With a proven track record of over 100 successful cGMP manufacturing batches and the development of more than 42 biologics and biosimilars, Bora Biologics exemplifies how experience drives success. We offer agile, comprehensive end-to-end CDMO solutions that optimize time and cost efficiencies for biopharma companies around the world. We specialize in a diverse range of biologics, including monoclonal antibodies (mAbs), bi-specifics, fusion proteins, recombinant proteins, and enzymes.
FAMAR is a leading European CDMO with over 75 years of experience, providing end-to-end solutions for the pharmaceutical and healthcare industries. With 7 manufacturing sites and 2 R&D centers across Germany, Greece, Italy, and Spain, it delivers quality, compliance and value across a broad portfolio of finished dosage forms.
